Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December - 2New heart disease calculator predicts 30-year risk for young adults
- 3You finally got a doctor's appointment. Here's how to get the most out of it
- 4Startled Venezuelans express relief but also fear after Maduro arrest
- 55 things for parents to know about changes to kids vaccine schedule
- Surveys of 6 Hot Savvy Beds
- California is completely free of drought for the first time in 25 years
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Factbox-China's crewed lunar programme eyes astronaut landing by 2030
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- Iran War Derails The Automotive Industry
- Vote in favor of your #1 Kind of Cap
